Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand

Diabetes

Volumn 55, Issue 1, 2006, Pages 202-208

  Vaidyula, Vijender R ^a   Rao, A Koneti ^a   Mozzoli, Maria ^a   Homko, Carol ^a   Cheung, Peter ^a   Boden, Guenther ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; CD40 LIGAND; GLUCOSE; INSULIN; MESSENGER RNA; PROCOAGULANT; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

ADULT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE;

EID: 33644750404     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.55.01.06.db05-1026     Document Type: Article

References (43)

1. Pan WH, Cedres LB, Liu K, Dyer A, Schoenberger JA, Shekelle RB, Stamler R, Smith D, Collette P, Stamler J: Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 123:504-516, 1986
2. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K: Five-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 82:27-36, 1990
3. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR: Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am Heart J 120:672-676, 1990
4. Laakso M, Lehto S: Epidemiology of macrovascular disease in diabetes. Diabetes Rev 5:294-315, 1997
5. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20:1262-1275, 2000
6. Osterman H, van de Loo J: Factors of the hemostatic system in diabetic patients. Haemostasis 16:386-416, 1986
7. Kwaan HC: Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes 41 (Suppl. 2):32-35, 1992
8. Kario K, Mastuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T: Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients and microalbuminuria. Arterioscler Thromb Vasc Biol 15:1114-1120, 1995
9. Morishita E, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Yamazaki M, Aoshima K, Hashimoto T, Matsuda T: Hypercoagulability and high lipoprotein (a) levels in patients with type II diabetes mellitus. Atherosclerosis 120:7-14, 1996
10. Jones RL: Fibrinopeptide-A in diabetes mellitus. Diabetes 34:836-843, 1985
11. Ceriello A, Giacomello R, Colatutto A, Taboga C, Gonano F: Hyperglycemia-induced thrombin formation in diabetes: the possible role of oxidative stress. Diabetes 44:924-928, 1995
12. Rao AK, Chouhan V, Chen X, Sun L, Boden G: Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 48:1156-1161, 1999
13. Rauch U, Nemerson Y: Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 10:139-143, 2000
14. Mackman N: Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24:1015-1022, 2004
15. Wilcox JN, Smith KM, Schwartz SM, Gordon D: Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 86:2839-2843, 1989
16. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 96:2311-2315, 1999
17. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR: Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 91:4216-4223, 1998
18. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B: Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 104:3190-3197, 2004
19. Abdel-Hafiz E, Vaidyula VR, Bagga S, London FS, Boden G, Rao AK: Elevated whole blood tissue factor procoagulant activity in diabetes mellitus: vitamin E inhibits glucose induced tissue factor activity in vitro (Abstract). Blood 100:496a, 2002
20. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ: Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107:973-977, 2003
21. Gerstein HC, Yusuf S: Dysglycaemia and risk of cardiovascular disease. Lancet 347:949-950, 1996
22. Diabetes Control and Complications Trial (DCCT) Research Group: Effect of intensive diabetes management on macrovascular event and risk factors in the diabetes control and complications trial. Am J Cardiol 75:894-903, 1995
23. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591-594, 1998
24. Phipps RP: Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A 97:6930-6932, 2000
25. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR: Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106:896-899, 2002
26. Jinchuan Y, Zonggui W, Jimming C, Li L, Xintao K: Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta 339:85-90, 2004
27. Harding SA, Sommerfiled AJ, Sarma J, Twomey PJ, Newby DE, Frier BM, Fox KA: Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 176:321-325, 2004
28. Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P: Thiazolidinediones upregulated fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 54:880-885, 2005
29. Zhou JN, Lijungdahl S, Shoshan MC, Swedengorg J, Linder S: Activation of tissue-factor gene expression in breast carcinoma cells by stimulation of the RAF-ERK signaling pathway. Mol Carcinog 21:234-243, 1998
30. Tutar E, Ozcan M, Kilickap M, Gulec S, Aras O, Pamir G, Oral D, Dandelet V, Key NS: Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation. Circulation 108:1581-1584, 2003
31. Amengual O, Atsumi T, Khamashta MA, Bertolaccini ML, Hughes GR: The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 79:276-281, 1998
32. Asakura H, Kamikubo Y, Goto A, Shiratori Y, Yamazaki M, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Aoshima K, Nakamura S, Matsuda T: Role of tissue factor in disseminated intravascular coagulation. Thromb Res 80:217-224, 1995
33. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y: Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 96:170-175, 2000
34. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y: Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9:458-462, 2003
35. Bach RR, Moldow CF: Mechanism of tissue factor activation on HL-60 cells. Blood 89:3270-3276, 1997
36. Taylor FB, Haddad PA, Hack E, Chang AC, Peer GT, Morrissey JH, Li A, Allen RC, Wada H, Kinasewitz GT: Two-stage response to endotoxin infusion into normal human subjects: correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Crit Care Med 29:326-334, 2001
37. Mesters RM, Mannucci PM, Coppola R, Keller T, Osterman H, Kienast J: Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 88:881-886, 1996
38. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102:2180-2184, 2000
39. Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ: Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A 7:7464-7469, 2000
40. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P: Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 97:7458-7463, 2000
41. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W: Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107:1954-1957, 2003
42. Bokarewa MI, Morrissey JH, Tarkowski A: Tissue factor as a proinflammatory agent. Arthritis Res 4:190-195, 2002
43. Libby P, Simon DI: Inflammation and thrombosis: the clot thickens. Circulation 103:1718-1720, 2001